PT  - JOURNAL ARTICLE
AU  - Wang, Liuyang
AU  - Balmat, Thomas J.
AU  - Antonia, Alejandro L.
AU  - Constantine, Florica J.
AU  - Henao, Ricardo
AU  - Burke, Thomas W.
AU  - Ingham, Andy
AU  - McClain, Micah T.
AU  - Tsalik, Ephraim L.
AU  - Ko, Emily R.
AU  - Ginsburg, Geoffrey S.
AU  - DeLong, Mark R.
AU  - Shen, Xiling
AU  - Woods, Christopher W.
AU  - Hauser, Elizabeth R.
AU  - Ko, Dennis C.
TI  - An atlas connecting shared genetic architecture of human diseases and molecular phenotypes provides insight into COVID-19 susceptibility
AID  - 10.1101/2020.12.20.20248572
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.12.20.20248572
4099  - http://medrxiv.org/content/early/2020/12/22/2020.12.20.20248572.short
4100  - http://medrxiv.org/content/early/2020/12/22/2020.12.20.20248572.full
AB  - While genome-wide associations studies (GWAS) have successfully elucidated the genetic architecture of complex human traits and diseases, understanding mechanisms that lead from genetic variation to pathophysiology remains an important challenge. Methods are needed to systematically bridge this crucial gap to facilitate experimental testing of hypotheses and translation to clinical utility. Here, we leveraged cross-phenotype associations to identify traits with shared genetic architecture, using linkage disequilibrium (LD) information to accurately capture shared SNPs by proxy, and calculate significance of enrichment. This shared genetic architecture was examined across differing biological scales through incorporating data from catalogs of clinical, cellular, and molecular GWAS. We have created an interactive web database (interactive Cross-Phenotype Analysis of GWAS database (iCPAGdb); http://cpag.oit.duke.edu) to facilitate exploration and allow rapid analysis of user-uploaded GWAS summary statistics. This database revealed well-known relationships among phenotypes, as well as the generation of novel hypotheses to explain the pathophysiology of common diseases. Application of iCPAGdb to a recent GWAS of severe COVID-19 demonstrated unexpected overlap of GWAS signals between COVID-19 and human diseases, including with idiopathic pulmonary fibrosis driven by the DPP9 locus. Transcriptomics from peripheral blood of COVID-19 patients demonstrated that DPP9 was induced in SARS-CoV-2 compared to healthy controls or those with bacterial infection. Further investigation of cross-phenotype SNPs with severe COVID-19 demonstrated colocalization of the GWAS signal of the ABO locus with plasma protein levels of a reported receptor of SARS-CoV-2, CD209 (DC-SIGN), pointing to a possible mechanism whereby glycosylation of CD209 by ABO may regulate COVID-19 disease severity. Thus, connecting genetically related traits across phenotypic scales links human diseases to molecular and cellular measurements that can reveal mechanisms and lead to novel biomarkers and therapeutic approaches.Competing Interest StatementThe authors have declared no competing interest.Funding StatementLW, TJB, AI, MRD, ERH, and DCK were supported by NIH R21AI133305. LW, ALA, and DCK were supported by NIH R01AI118903. FJC, RH, TWB, MTM, XS, ELT, ERK, and CWW were supported by DARPA/USMRAA W911NF1920111.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Samples were collected as part of the Molecular and Epidemiological Study of Suspected Infection (MESSI) which was conducted at Duke University Health System (DUHS) and the Durham Veterans Affairs Health Care System (DVAHCS). The study was approved by each institution IRB.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRequests for resources should be directed to and will be fulfilled by the Lead Contact, Dennis C. Ko (dennis.ko{at}duke.edu). All iCPAGdb output described in this manuscript are available for browsing from http://cpag.oit.duke.edu. Supplemental files also contain iCPAGdb output and COLOC analysis results. Code is available at GitHub https://github.com/tbalmat/iCPAGdb. http://cpag.oit.duke.edu https://github.com/tbalmat/iCPAGdb